Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2015-11-12 M&A Activity
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
SC TO-I/A Filing
M&A Activity Classification · 100% confidence The document is a Schedule TO filing, specifically Amendment No. 3, related to a tender offer by Theravance, Inc. It references the Securities Exchange Act of 1934 and Rule 13e-4, which governs issuer tender offers. The document includes details about the tender offer, exhibits such as the Offer to Purchase, Letter of Transmittal, and other related materials. It also includes a calculation of the filing fee and certifications by the CEO. The presence of terms like 'Tender Offer Statement', 'Schedule TO', and references to Rule 13e-4 clearly indicate this is a filing related to a tender offer transaction. This matches the definition of M&A Activity filings, which cover announcements and documents related to merger proposals or takeover bids, including tender offers. The document is not a full annual or quarterly report, nor is it a simple announcement or certification. Therefore, the correct classification is TAR (M&A Activity). The document length and detail support a high confidence level.
2015-11-12 English
SC TO-I/A Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO filing, specifically an Amendment No. 2 to a Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934. It relates to an issuer tender offer by Theravance, Inc. to purchase its own common stock. The content includes detailed terms and conditions of the tender offer, amendments to the offer, and exhibits related to the offer documents. This type of filing is directly related to a tender offer transaction, which falls under merger and acquisition activity filings. The document is not an announcement of a report, nor is it a financial report or certification. Therefore, the correct classification is Merger & Acquisition (MA).
2015-11-10 English
10-Q
Interim / Quarterly Report 9M 2015
2015-11-05 English
SC TO-I/A Filing
Merger & Acquisition Classification · 100% confidence The document is a Schedule TO (Tender Offer Statement) Amendment No. 1 filed with the SEC by Theravance, Inc. It relates to an issuer tender offer under Rule 13e-4 of the Securities Exchange Act of 1934. The document includes detailed information about the tender offer, references to related filings such as the Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other exhibits. The primary purpose is to amend and supplement the original Schedule TO filing regarding the tender offer. This type of filing is specifically related to merger and acquisition activity, particularly tender offers. Therefore, the correct classification is Merger & Acquisition (MA). The document length (12,465 characters) and content confirm it is a substantive filing, not just an announcement or certification.
2015-11-05 English
SC TO-I Filing
M&A Activity Classification · 95% confidence The document is titled 'Schedule TO' and is described as a 'Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934.' It relates to Theravance, Inc.'s offer to purchase its own common stock for cash, with detailed terms of the tender offer, including purchase price, procedures, and conditions. The document references the Offer to Purchase and related Letter of Transmittal, which are typical exhibits in tender offer filings. There are no financial statements or earnings data presented, and the document is not an announcement of a report but the actual tender offer statement filing. This matches the definition of a filing related to merger or acquisition activity, specifically a tender offer statement. Therefore, the appropriate classification is 'TAR' (M&A Activity). The document length and detail support a high confidence level.
2015-10-30 English
SC TO-C Filing
M&A Activity Classification · 95% confidence The document is a Schedule TO filing with the SEC, which is a Tender Offer Statement under the Securities Exchange Act of 1934. It relates to a preliminary communication before the commencement of a tender offer by Theravance, Inc. The text explicitly states it is a preliminary communication and not the tender offer itself. The document includes details about the tender offer, contact information, and a certification by the CFO. It also references an exhibit which is a transcript of the third quarter earnings call, but the main document is focused on the tender offer preliminary communication. According to the filing definitions, documents related to merger proposals or takeover bids, including tender offer filings such as Schedule TO, fall under the category 'M&A Activity' (Code: TAR). The document length is over 5,000 characters and contains substantive information about the tender offer, so it is not merely an announcement. Therefore, the correct classification is 'TAR' with high confidence.
2015-10-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.